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by PET/CT scan. No difference in staging was seen in 26 cases (37%). 
3 cases (4%) could not be assessed because of incomplete records. 
In 19 out of 67 cases (28%) PET/CT scan changed the management 
decision from radical to palliative treatment and in 11 cases (17%) 
the management changed from palliative to radical treatment. Overall 
the difference in staging led to a change in management in 30 patients 
(45%). Congruent results were seen in 37 cases (55%).
Conclusion: This was a small retrospective study. However, it 
conﬁrmed that PET/CT is invaluable for the correct management of 
NSCLC patients. This ﬁgure is consistent with current literature where 
40-45% of changes in management are quoted. 
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Role of PET in evaluation of lung cancer
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PET is a widely used diagnostic method of nuclear radiology in the 
diagnosis and evaluation of malignancies. Apart from other malignan-
cies PETespecially has an important role in diagnosis, staging and 
therapy of lung cancer in our daily practice. In this study we evaluated 
retrospectively our patients whom PET was used during their therapies. 
Prediagnosis of the patients, the role of PET in disease staging, and the 
role of PET in therapy changes were analised. 34 patients were evalu-
ated, consisting 30 male, 4 female. The patients median age was 55. 
PET, was performed to ﬁnd the primery site of metastasis in 11 cases, 
primary tumor relaps after lung cancer surgery in 4 cases, preoperative 
assesement in 14 cases and for staging after neuadjuvant therapy in 5 
cases. PET staging made the clinic stage up in 13 of 23 lung cancer 
patients and down in 4 patient. In 6 patients PET didn’t change the 
clinic stage. 
Conclusion: PET should be thought in stagingthe lung cancer patients 
especially who will be planned to treat with invazive therapy modalities
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Lung cancer cases detected by repeated low-dose CT screening
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Purpose: To review lung cancer cases detected by repeated low-dose 
CT screening, and then to clarify pitfalls in interpretation and observa-
tion of repeated screenee.
Methods: From May 2000 to March 2005, asymptomatic 4,176 sub-
jects (2,490 male and 1,686 female) underwent low-dose CT screening. 
A total 13 subjects were found to have lung cancer over a period of 5 
years. Among them, 3 cases were repeated screenee case. These 3 cases 
were reviewed gender, age, smoking pack years, tumor size, histologi-
cal subtype, disease stage and repeated CT images.
Results: Case one was 61 years old female with well differentiated ad-
enocarcinoma of stage IA disease. She underwent 3 times of CT screen-
ing until diagnosed lung cancer. First time her lesion was estimated 
post inﬂammatory scar, but it was gradually grown in size. Second case 
was 66 years old male with small cell carcinoma of stage IIA disease. 
He underwent 4 times of CT screening until diagnosed lung cancer. 
Until second repeated CT screening, his thoracic CT images were no 
evidence of disease. In 3rd CT screening, he was detected small nodule 
in peripheral lung, but it was disappeared. In 4th CT screening, left 
hilar lymphadenopathy was detected. Trans-bronchial biopsy specimen 
proved small cell carcinoma. Third case was 58 years old male with 
squamous cell carcinoma of stage IIIA disease. He underwent 2 times 
of CT screening until diagnosed lung cancer. He was detected a nodule 
in ﬁrst CT screening, but it was estimated decreased in size. In second 
CT screening, this nodule was grown in size again. First case of female 
was never-smoker, but second and third cases were 92 and 38 pack-
years smoker, respectively.
Conclusions: Many of the lung cancers detected by low-dose CT 
screening were early stage disease. On the other hand, there is rapid 
growth case in a short period, we must remember these case can be 
detected by faint change in a comparative interpretation and a strict 
observation. Especially, nodules detected in heavy-smoking screenee 
must be paid attention to the faint change.
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Objective: The aim of the present study was to test the use of EBUS 
TBNA and EUS FNA in patients with an undiagnosed solid lesion of 
unknown origin in the lung or mediastinum
Methods: 
EBUS TBNA and EUS FNA was performed before mediastinoscopy.
52 patients prospective referred - 5 patients with a tumour in the medi-
astinum 47 patients with an undiagnosed tumour in the lung.
Bronchoscopy and TBNA had been performed in all patients without 
obtaining a diagnose.
103 lymph nodes and 5 tumours were biopsied
All the diagnosis was confrmed either by mediastinoscopy, thoracoto-
my/ thoracoscopy
Results: 
103 lymph nodes and 5 tumours were biopsied
EBUS TBNA positive for cancer in 34 lymph nodes
EUS FNA positive for cancer in 37 lymph nodes 
EUS and EBUS positive for cancer in 2 tumours
EUS and EBUS showed speciﬁc benign changes i 3 tumours
In one patient both EUS FNA and EBUS TBNA shoved benign changes 
and a cancer was found in a N1 lymph nodes during operation
3 biopsies were inconclusive and 32 lymph nodes biopsies showed cor-
rectly normal lymph cells 
The diagnostic yield was 97% (105/108) 
31 patients were diagnosed with a malignant diagnosis and 3 patients 
with a speciﬁc benign diagnosis
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS580
The combined procedure was diagnostic in 67% of the patients(52/67)
Conclusions: EBUS TBNA and EUS FNA is both effective and non 
invasive methods to obtain a diagnose in patients with lesions of un-
known origin in the lungs and mediastinum
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Objective: The aim of the present study was to compare the results 
from EBUS-TBNA with standard medi-astinoscopy in the evaluation of 
mediastinal lymph nodes in patients with lung cancer or undiag-nosed 
solid lesion in the mediastinum 
Methods: The combination of EBUS TBNA and mediastinoscopy was 
prospective performed in 66 patients during the same general anaesthe-
sia.
Results: A total of 66 patients (29 females and 37 males mean age 60 
years) underwent EBUS TBNA and Mediastinoscopy combined. 
I 61 patients (93%) EBUS TBNA the result was consistent with the 
ﬁnal diagnose and the medi-astnoscopy was correct in 53 patients 
(80%). In one patient both mediastinoscopy and EBUS TBNA was 
false negative.
The ﬁnal diagnose for the patients were 55 cancers, 1 tuberculosis. 1 
lymphoma, 3 sarcoidosis and 6 inﬂamations.
NPV and PPV for the two methods will be discussed.
Conclusions: EBUS-TBNA is an accurate, safe and minimally invasive 
diagnostic technique for the staging of mediastinal lymph nodes. It’s 
routine use for this purpose instead of mediastinoscopy should be 
considered 
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Background: Early and precise response evaluation is of great value 
in patients (pts) with advanced/metastatic NSCLC in order not only to 
reduce toxicity and additional cost by ineffective and unnecessary toxic 
treatment but also to get a chance to receive other possible effective 
treatments earlier. We conducted a prospective study to evaluate 18-
ﬂuorodeoxyglucose positron emission tomography-computed tomogra-
phy (PET-CT) for early prediction of response and survival.
Methods: Between May 2004 and November 2005, 31 pts [gender, 
23M, 8F; stage, 2IIIB, 29IV, histology, 6 squamous cell ca, 22 adenoca, 
3 NOS; age, median 57 (30-73 yr)] with pathologically proven NSCLC 
stage IIIB/IV participated into this study. PET response or metabolic 
response was measured prospectively according to recommendations of 
the EORTC PET study group after one cycle of treatment. Radiologic 
response or best overall response was determined according to WHO 
response criteria every 3 cycles or when clinically indicated.
Results: Pts underwent systemic treatment with gemcitabine/vinorel-
bine (15), gemcitabine/cisplatin (1) gemcitabine/vinorelbine/cisplatin 
(1), irinotecan/cisplatin (9) or geﬁtinib (5). Out of 31 pts, there were 
12 PRs (38.7%), 5 SDs and 14 PDs. Out of 13 progressive metabolic 
diseases (PMD), there were 9 PRs, 3 SDs and 1 PR, while all of 7 
partial metabolic responses (PMR) were conﬁrmed to reach PR. When 
increased pleural effusion identiﬁed on PET-CT was deﬁned as PMD, 
there were 17 PMDs, of which there were 13 PDs, 2 SDs and 2 PR. 
As radiologic response was signiﬁcantly correlated with time-to-pro-
gression and survival time (p<0.001 and p=0.015, respectively), early 
metabolic response was signiﬁcantly correlated with them (p<.0.001 
and p=0.031, respectively).
Conclusions: FDG-PET-CT can predict early he best response to 
treatment. Therefore, the early use of FDG-PET-CT can reduce side 
effects and costs of ineffective therapy in non-responding patients and 
may early predict response to new therapeutic agents. However, the 
patients showing equivocal metabolic response will be reassessed by 
subsequent response evaluation. Our study needs to be validated in a 
larger series.
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Lung cancer in patients younger than 40 years of age: imaging 
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Background: Lung cancer is rarely found in young patients, especially 
in those younger than 40 years of age. It has been suggested that the 
clinical features, pathologic ﬁndings, and prognosis in young patients 
with lung cancer differ from those in elderly patients with lung cancer. 
The aim of this study was to describe the CT features of lung cancer in 
patients under the age of 40.
Methods: We retrospectively reviewed demographic ﬁndings, histol-
ogy and staging of lung cancer under the age of 40 years among 6,876 
patients who were diagnosed to have primary lung cancer at our hos-
pital during the period from 2001 to 2006. CT ﬁndings were retrospec-
tively assessed in terms of the location (peripheral or central), shape 
(mass or consolidation) and size of primary tumor, presence of pleural 
or pericardial effusion and pleural nodules and pattern of lung metas-
tasis [micronodular (< 5mm), macronodular (≥ 5mm), or lymphangitic 
metastasis].
Results: Primary lung cancer was diagnosed in 132 patients (1.9%). 
They were 70 men and 62 women with mean age of 34 years (range 13 
- 39 years). One hundred patients (76%) had adenocarcinoma; 11 (8%), 
non small cell carcinoma-not otherwise speciﬁed; 9 (7%), squamous 
cell carcinoma; 8 (6%), small cell carcinoma; 2 (2%), adenosquamous 
cell carcinoma; and one each (1%), sarcomatoid carcinoma and muco-
epidermoid carcinoma. At the time of diagnosis 9 (7%) had stage I, 1 
(1%) stage II, 30 (23%) stage III, and 92 (70%) stage IV. 
In 117 patients, 50 lesions were located in central and 67 were in 
peripheral. Fifteen lung cancers were consolidation type. The longest 
